EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseOpen Access · CC BY-NC-ND 4.0

A systematic review and meta‐analysis of clinical trials assessing safety and efficacy of human extracellular vesicle‐based therapy

Mats Van Delen iD, Judith Derdelinckx, Kristien Wouters, Inge Nelissen, Nathalie Cools

Journal of Extracellular Vesicles · 2024-07 · 13 (7)

DOI: 10.1002/jev2.12458 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Journal of Extracellular Vesicles, online erschienen am 03.07.2024. Verfasst von Mats Van Delen und 4 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Experimental Hematology, Vaccine and Infectious Disease Institute (Vaxinfectio), University of Antwerp, Antwerpen, Belgium. Hauptthemen laut MEDLINE: Extracellular Vesicles, Clinical Trials as Topic. Die Arbeit wurde bisher 166-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Fondation Charcot, Vlaamse Instelling voor Technologisch Onderzoek, Universiteit Antwerpen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Nowadays, it has become clear that extracellular vesicles (EVs) are not a cellular waste disposal vesicle but are an essential part of an intercellular communication system. Besides the use of EVs in biomarker studies and diagnostics, the potential of EV‐therapeutics has been seen by many. They provide unique properties for disease therapy, including strong immune‐modulatory actions, the possibility of engineering, low immunogenicity, and the capability of crossing biological barriers. Proof‐of‐concept of EV‐therapeutics for various pathologies has been achieved in preclinical studies. However, clinical trials with EVs have only been emerging slowly. Here, we aim to provide a comprehensive overview of the current state‐of‐the‐art concerning clinical studies using EVs in human therapy. By approaching the current knowledge in a systematic manner, we were able to include 21 reports for meta‐analysis of safety and evaluation of efficacy outcomes. Overall, we have shown that EV‐based therapy is safe with a low incidence of serious adverse events (SAE; 0.7% (95%‐CI: 0.1–5.2%), and adverse events (AE; 4.4% (95%‐CI: 0.7–22.2%). Subgroup analysis showed no significant difference in SAE when comparing autologous versus allogeneic administration, as well as engineered versus non‐engineered EV products. A significantly higher number of AE was seen in autologous versus allogeneic administration. However, the clinical relevance remains questionable. Evaluation of the clinical outcomes of immunostimulatory, immunosuppressive or regenerative EV‐therapies indicated improvement in the majority of treated patients. Despite these promising results, data need to be approached with caution due to a high heterogeneity in the EVs manufacturing methods, study design, and reporting of (S)AE. Overall, we conclude that EV‐based therapy is safe and presents a promising opportunity in therapy. More efforts are needed in the standardization and harmonization of reporting of EV isolation and characterization data as well as in the reporting of (S)AE to allow inter‐study comparison.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Extracellular VesiclesClinical Trials as TopicHumans

Stichwörter der Autor:innen

clinical studiesexosomeextracellular vesiclesmeta‐analysissafetysystematic reviewtherapy

Autor:innen und Institutionen

  • Laboratory of Experimental Hematology, Vaccine and Infectious Disease Institute (Vaxinfectio), University of Antwerp, Antwerpen, Belgium.
  • Health Department, Flemish Institute for Technological Research (VITO), Mol, Belgium.
  • Clinical Trial Center (CTC), CRC Antwerp, Antwerp University Hospital, University of Antwerp, Edegem, Belgium.
  • Department of Neurology, Antwerp University Hospital, Edegem, Belgium.
  • Center for Cell Therapy and Regenerative Medicine (CCRG), Antwerp University Hospital, Edegem, Belgium.

ORCID-Profile: Mats Van Delen

Förderung

  • Fondation Charcot
  • Vlaamse Instelling voor Technologisch Onderzoek
  • Universiteit Antwerpen

Zitieren

APA

Van Delen, M., Derdelinckx, J., Wouters, K., Nelissen, I., & Cools, N. (2024). A systematic review and meta‐analysis of clinical trials assessing safety and efficacy of human extracellular vesicle‐based therapy. Journal of Extracellular Vesicles, 13(7). https://doi.org/10.1002/jev2.12458

Vancouver

Van Delen M, Derdelinckx J, Wouters K, Nelissen I, Cools N. A systematic review and meta‐analysis of clinical trials assessing safety and efficacy of human extracellular vesicle‐based therapy. Journal of Extracellular Vesicles. 2024;13(7). doi:10.1002/jev2.12458

BibTeX
@article{VanDelen2024,
  author = {Van Delen, Mats and Derdelinckx, Judith and Wouters, Kristien and Nelissen, Inge and Cools, Nathalie},
  title = {A systematic review and meta‐analysis of clinical trials assessing safety and efficacy of human extracellular vesicle‐based therapy},
  journal = {Journal of Extracellular Vesicles},
  year = {2024},
  volume = {13},
  number = {7},
  doi = {10.1002/jev2.12458}
}
Kostenlos starten →